Triptans and NSAIDs: Key Players in Migraine Management in England

Research Summary

A recent study published in BMC Primary Care explores the use of triptans and other acute migraine treatments in England's routine clinical practice. Analyzing data from the Clinical Practice Research Datalink, the study highlights that triptans are prescribed to 64% of migraine patients, reflecting their common use in managing acute migraine episodes. Additionally, the study finds that non-steroidal anti-inflammatory drugs (NSAIDs) are used by 35% of patients, indicating their significant role in treatment strategies. The findings underscore the prevalence of these therapies and provide insights into current clinical practices, helping to inform future strategies for improving migraine management.

Study Details

📄 Title: The use of triptans and other acute treatments for the management of migraine in routine clinical practice in England: a retrospective cohort study using the Clinical Practice Research Datalink (CPRD).

👥 Research Team: Collings SL et al.

📚 Published In: BMC Prim Care

📅 Publication Date: 2025 Dec 9

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.